Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kassim Javaid has been announced as one the successful applicants of The Royal Osteoporosis Society’s largest ever research grants round.

Horizontal portrait of Kassim Javid

Half of women and one fifth of men will break a bone due to osteoporosis. The Royal Osteoporosis Society research grants programme aims to change that, by offering researchers at various stages in their careers the opportunity to apply for funding that will allow them to undertake pioneering research and improve our understanding of osteoporosis.

Dr Kassim Javaid, Associate Professor at NDORMS is one of the successful applicants for his research proposal into real world data audits to help identify high-risk fracture patient and the impacts on secondary fracture prevention.

Kassim said: "We were delighted to hear that the ROS has supported our research project. Our research will help patients, who have recently broken a bone after a fall, receive the best care possible to reduce their risk of another broken bone. Our team of researchers and patients will work to understand the ingredients that make fracture liaison services run well. We will also identify patients at higher risk of another hip fracture and may need to be fast-tracked to more stronger bone treatments."

Dr Caroline Sangan, Research Manager at the ROS, said: "We've been really impressed with the quality of applications we received as part of this year's research grants programme. Five project grants, one early career grant and one innovative grant have been chosen.

"Each application was reviewed by our Research Grants Assessment Panel before being peer reviewed, to ensure that we fund research of the highest standard that also meets our objectives as a charity. We were pleased to see this year's successful applicants included detailed plans on how they'd involve individuals with experience of osteoporosis in their research, with over 50% even including them as a co-applicant."

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.